# Mark C. Genovese

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-c-genovese/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,618 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 89 |
| i10-index | 220 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5100607192 |
| ORCID iD | https://orcid.org/0000-0001-5294-4503 |
| Works | 434 |

## Researcher papers

- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-in-combination-with-nonbiologic-disease-modifying-antirheumatic/)
- [Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial](https://scholariq.org/papers/ixekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis-and-an/)
- [Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs](https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/)
- [Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial](https://scholariq.org/papers/reduced-b-lymphocyte-and-immunoglobulin-levels-after-atacicept-treatment-in/)
- [Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus](https://scholariq.org/papers/factors-that-predict-prematurity-and-preeclampsia-in-pregnancies-that-are/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.